Source: Canadian Agency for Drugs and Technologies in Health (CADTH)
Area: News
The Canadian Agency for Drugs and Technologies in Health (CADTH) has published the results of a systematic review of randomised controlled trials (RCTs) of intravitreal bevacizumab (IVB) for the treatment of diabetic macular oedema (DMO). The purpose of the research was to determine whether IVB provides a therapeutic advantage in terms of visual acuity, morbidity, and/or mortality, in comparison with other standard therapy (intravitreal injection of triamcinolone, pegaptanib, or ranibizumab, or other drug therapies; and laser photocoagulation), sham (Read more...)
Uncategorized